





1

2

3

4

5

6



2023

1/2







® PD-1

1H23 5.56

3 ES-SCLC

ES-SCLC

PD-1

3 ES-SCLC

MAA EMA

9 ESCC






®






®

®

®










CDE 2021 7



DRG/DIP



药友制药 | FOSUN PHARMA  
 万邦医药 | FOSUN PHARMA  
 麒麟医药 | FOSUN PHARMA



Alma

FOSUN IDGENVAX  
复星安特金

cenexi  
 creating innovative partnerships  
 Gland Pharma  
 2023 4  
 CDMO Cenexi



mRNA

SOBI  
 RT002

AMGEN 安进  
 Parsabiv




2019 - 2022

2023 - 2024

NDA/BLA

Ph3



Gland



Gland Pharma <b>Cenexi</b>	<b>CDMO</b>	2023	4
10	<b>Intas</b>	4200	*






5	800	2022
<b>ICRC</b>		

Gland Pharma	2023	2
<b>CDMO</b>	Gland Pharma	200

16	GPO	5
<b>SCLC</b>	PD-1	10
Syneos Health		<b>ES-</b>
PD-1		


# MSCI-ESG A









1



2,3



3



4

16.80% YoY

2,884

16.80% YoY

1,818

2,134

1H22

22.16% YoY


2,062

2,519

20.19% YoY

1,792

# SCLC PD-1



(ASTCT)

r/r LBCL

2023 6 r/r LBCL

CAR-T

B LBCL  
LBCL NHL 45.8%  
1.3

NHL  
LBCL 4

500

2023 6

140

25

10,000

GMP

2023 6

60

90

FL

MZL

2021 8

r/r FL

Kite Pharma

CAR-T  
/ B



Tecartus™

2020 7

FDA  
r/r ALL

/

MCL









-

1



1,2


1





1H23 b•





1H23

1,100

2000

FDA

8,042

2023

6

55,000

1,000

34

330

Ion

2019 Ion

FDA


2021 10 Ion

Ion






1




2011-2017

2,3



2018-2020

3



2021

6,448 \* 9

JCI

1H23



600

2017 11 9.09  
60%



1,750

2022

21.45

1.11

87.41%

900

800

2022 1 70%














\*

2023 6





		®		
		®		
		®		
		®		
		®		

		®		
		®		
		®		
		®		
		®		
		®		

		®		
		®		
		®		
		®		



# 1/2

			/		IND	1	2	3	NDA
HLX10 <sup>1</sup>	+		PD-1	/	III 2022 11				
					2022 11	2022 FDA/EC	2023 1		
	+ +		PD-1			III 2023 1	2022 5		
	+		PD-1+VEGF						
	+HLX07		PD-1+EGFR						
	+HLX07 +		PD-1+EGFR +VEGF		2022 1				
HLX07		EGFR							
HLX22									
HLX11	2		HER2		III 2022				
HLX05	3		EGFR						
HLX02	4		HER2		FDA 2020				

1 KG Bio 10  
3  
5 2023 10 31

2 Organon  
4 Accord Cipla Jacobson mAbxience Eurofarma Abbott





# 1/2

		/		IND	1	2	3	NDA
FCN-437c		CDK4/6	1L					
			2L					
SAF-189		ALK/ROS1	ALK+	2022 1 NMPA III				
			ROS1+					
HLX-208	-	BRAF	Erdheim-Chester ECD LCH	2023 4 LCH ECD NMPA				
		BRAF+PD-1	BRAF V600E BRAF V600					
FCN-159		MEK	I	2023 7 NMPA II				
				2023 4 NMPA 2022 5 NMPA				
YP01001		VEGFR	NMPA					
FCN-338		BCL-2		NMPA				
			B					
FH-2001		FGFR/PD-L1						
ORIN1001		IRE1						

# 2/2

	/		IND	1	2	3	NDA
	TPO-R	ITP					
Tenapanor	NHE 3	(ESRD-HD)					
	P-CAB		I				
Tenapanor	NHE 3	(IBS-C)	I				
PA-824	-	XDR-TB / MDR-TB	Pretomanid*				
Opicapone	COMT		Ongentys*				
Fortacin	-		-				
ET-26	-		2023 10	III			
FCN-159	MEK						
ORIN1001	IRE1		I				
FCN-016	ROCK		2023 1	NMPA			
SZEY-2108	-	CRE	2023 6	NMPA			

			IND	1	2	3	NDA
	/						
	/						
	/						
13							
24							
23							
	-						

2023 10 31

LOGO

Fosun Pharma, the Representer or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representer or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and , § , Fosun , , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.

FOSUN PHARMA

复星医药

持续创新 守护健康



[www.fosunpharma.com](http://www.fosunpharma.com)